Omnicell (NASDAQ:OMCL) Rating Lowered to “Hold” at StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

A number of other brokerages have also recently weighed in on OMCL. Bank of America reaffirmed a “neutral” rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Craig Hallum lifted their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. increased their price target on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Benchmark reaffirmed a “buy” rating and issued a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $52.00.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $48.46 on Wednesday. The business has a 50-day moving average of $44.51 and a two-hundred day moving average of $37.83. The firm has a market capitalization of $2.24 billion, a PE ratio of -124.25, a P/E/G ratio of 34.92 and a beta of 0.81. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Institutional Trading of Omnicell

Several large investors have recently modified their holdings of OMCL. Arizona State Retirement System lifted its stake in shares of Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after acquiring an additional 357 shares in the last quarter. Diversified Trust Co raised its position in shares of Omnicell by 3.3% in the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after purchasing an additional 494 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Omnicell by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after buying an additional 600 shares during the last quarter. Finally, Curi RMB Capital LLC grew its position in shares of Omnicell by 0.7% during the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after buying an additional 651 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.